Evidence map›Paper›PMID 34745440›Full record

ArticleBiochemistry (Moscow) Supplement. Series B, Biomedical chemistry2021

Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor.

R Sh Bibilashvili, M V Sidorova, U S Dudkina, M E Palkeeva, A S Molokoedov, L I Kozlovskaya, A M Egorov, A A Ishmukhametov, E V Parfyonova

Abstract read
In one paragraph

Article in Biochemistry (Moscow) Supplement. Series B, Biomedical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Peptide foldamer-based inhibitors of the SARS-CoV-2 S protein-human ACE2 interaction.Journal of enzyme inhibition and medicinal chemistry · 2023
    Article
  3. Review
  4. Will Peptides Help to Stop COVID-19?Biochemistry. Biokhimiia · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

R Sh BibilashviliNational Medical Research Center for Cardiology, 3rd Cherepkovskaya 15А, 121552 Moscow, Russia.
M V SidorovaNational Medical Research Center for Cardiology, 3rd Cherepkovskaya 15А, 121552 Moscow, Russia.
U S DudkinaNational Medical Research Center for Cardiology, 3rd Cherepkovskaya 15А, 121552 Moscow, Russia.
M E PalkeevaNational Medical Research Center for Cardiology, 3rd Cherepkovskaya 15А, 121552 Moscow, Russia.
A S MolokoedovNational Medical Research Center for Cardiology, 3rd Cherepkovskaya 15А, 121552 Moscow, Russia.
L I KozlovskayaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological products of the Russian Academy of Sciences, 108819 Moscow, Russia.
A M EgorovChumakov Federal Scientific Center for Research and Development of Immune-and-Biological products of the Russian Academy of Sciences, 108819 Moscow, Russia.
A A IshmukhametovChumakov Federal Scientific Center for Research and Development of Immune-and-Biological products of the Russian Academy of Sciences, 108819 Moscow, Russia.
E V ParfyonovaNational Medical Research Center for Cardiology, 3rd Cherepkovskaya 15А, 121552 Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the design of chimeric molecules consisting of two 22-23-mer peptides linked to each other by disulfide bonds was carried out. The chimeric molecule X1 was a disulfide dimer, in which terminal cysteine residues in the precursor molecules h1 and h2 were connected by the S-S bond. In the chimeric molecule X2, the disulfide bond was located in the middle of each precursor peptide molecule. The precursors h1 and h2 mimic amino acid sequences of α1- and α2-helices of the ACE2 extracellular peptidase domain, respectively, keeping intact most of the amino acid residues involved in the interaction with RBD. The aim of the work was to evaluate the binding efficiency of chimeric molecules and their constituent peptides with RBD (particularly in dependence of the middle and terminal methods of fixing the initial peptides h1 and h2). The proposed polypeptides and chimeric molecules were synthesized by chemical methods, purified to 95-97% purity, and characterized by HPLC and MALDI-TOF mass spectrometry. Binding of these peptides to the SARS-CoV-2 RBD was evaluated by microthermophoresis with recombinant domains corresponding in sequence to the original Chinese (GenBank ID NC_045512.2) and the British (B. 1.1.7, GISAID EPI_ISL_683466) variants. The original RBD of the Chinese variant bound to three synthesized peptides: linear h2 and both chimeric variants. Chimeric peptides were also bound to the RBD of the British variant. The antiviral activity of the proposed peptides was evaluated in Vero cell line.

Indexed as

ACE2computer simulationpeptide inhibitorRBDSARS-CoV-2

Identifiers

PMID34745440
PMCPMC8562373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.